Alastair MacKinnon - Mereo Biopharma Chief Medical Officer and Co-Founder

MREO
 Stock
  

USD 1.00  0.11  12.36%   

  Founder
Dr. Alastair G. MacKinnon is Chief Medical Officer and CoFounder of the Company. Prior to Mereo, he worked for Phase4 Partners, a global life science VC firm, having originally joined Nomura in 2005. Before Nomura, he was a practising physician in the United Kingdom for 10 years. Dr MacKinnon received a BSc and MBBS from Kings College London, is a Member of the Royal College of Surgeons of Edinburgh and has a Diploma in Corporationrationrate Finance from the London Business School. Dr MacKinnon is a board member of Phase4 Partners.
Age: 44    Ph.D    
44 33 3023 7300  https://www.mereobiopharma.com

Mereo Biopharma Management Efficiency

Mereo Biopharma Group has return on total asset (ROA) of (13.82) % which means that it has lost $13.82 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 34.85 %, meaning that it created $34.85 on every $100 dollars invested by stockholders. Mereo Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 16.76 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Mereo Biopharma Group has a current ratio of 7.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Mereo Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Mereo Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mereo Biopharma Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mereo to invest in growth at high rates of return. When we think about Mereo Biopharma's use of debt, we should always consider it together with cash and equity.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. Mereo Biopharma Group (MREO) is traded on NASDAQ Exchange in USA and employs 49 people.

Mereo Biopharma Group Leadership Team

Elected by the shareholders, the Mereo Biopharma's board of directors comprises two types of representatives: Mereo Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo Biopharma's management team and ensure that shareholders' interests are well served. Mereo Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Bains, Non-Executive Independent Director
Kunal Kashyap, Non-Executive Director
Deepa Pakianathan, Non-Executive Director
Paul Blackburn, Non-Executive Independent Director
Alastair MacKinnon, Chief Medical Officer and Co-Founder
Michael Wyzga, Non-Executive Director
Richard Jones, CFO, Executive Director
Richard Francis, Head of Pharmaceutical Development
John Richard, Head of Corporate Development and Co-Founder
Charles Sermon, Co-Founder, General Counsel, Secretary
Denise ScotsKnight, CEO, Co-Founder, Executive Director
Peter Fellner, Independent Non-Executive Chairman of the Board
Anders Ekblom, Non-Executive Independent Director

Mereo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mereo Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mereo Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mereo Biopharma's short interest history, or implied volatility extrapolated from Mereo Biopharma options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Mereo Biopharma Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Correlation Analysis. Note that the Mereo Biopharma Group information on this page should be used as a complementary analysis to other Mereo Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Mereo Stock analysis

When running Mereo Biopharma Group price analysis, check to measure Mereo Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo Biopharma is operating at the current time. Most of Mereo Biopharma's value examination focuses on studying past and present price action to predict the probability of Mereo Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Mereo Biopharma's price. Additionally, you may evaluate how the addition of Mereo Biopharma to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Mereo Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo Biopharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo Biopharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo Biopharma's market value can be influenced by many factors that don't directly affect Mereo Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Mereo Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.